214 related articles for article (PubMed ID: 8055814)
1. [Response of growth hormone to sandostatin and bromocriptine and prognostic value of prolactin levels in serum and thyroliberin test in patients with active acromegaly].
Gasińska T; Nowak S
Endokrynol Pol; 1993; 44(4):455-65. PubMed ID: 8055814
[TBL] [Abstract][Full Text] [Related]
2. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.
van der Lely AJ; Harris AG; Lamberts SW
Clin Endocrinol (Oxf); 1992 Aug; 37(2):181-5. PubMed ID: 1395069
[TBL] [Abstract][Full Text] [Related]
3. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas.
Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ
J Clin Endocrinol Metab; 1985 Jun; 60(6):1148-53. PubMed ID: 3923021
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of acromegalic patients with a good response to octreotide, a somatostatin analogue.
Yang IM; Woo JT; Kim SW; Kim JW; Kim YS; Choi YK
Clin Endocrinol (Oxf); 1995 Mar; 42(3):295-301. PubMed ID: 7758235
[TBL] [Abstract][Full Text] [Related]
5. Long-term bromocriptine therapy and predictive tests in acromegaly.
Karashima T; Kato K; Nawata H; Ikuyama S; Ibayashi H; Okamura K; Shiroozu A; Nakashima T; Fujishima M
Endocrinol Jpn; 1986 Apr; 33(2):163-7. PubMed ID: 3093202
[TBL] [Abstract][Full Text] [Related]
6. The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly.
Lamberts SW; Liuzzi A; Chiodini PG; Verde S; Klijn JG; Birkenhäger JC
Eur J Clin Invest; 1982 Apr; 12(2):151-5. PubMed ID: 6807686
[TBL] [Abstract][Full Text] [Related]
7. [The relationship between TSH response to TRH and GH response to dopaminergic agents in patients with acromegaly].
Tokuyama T; Yoshinari M; Okamura K; Ikenoue H; Sato K; Kuroda T; Fujishima M
Nihon Naibunpi Gakkai Zasshi; 1991 Feb; 67(2):65-74. PubMed ID: 1674920
[TBL] [Abstract][Full Text] [Related]
8. Effect of bromoergocriptine on TRH-induced growth hormone and prolactin release in acromegalic patients.
Ishibashi M; Yamaji T; Kosaka K
J Clin Endocrinol Metab; 1977 Aug; 45(2):275-9. PubMed ID: 407240
[TBL] [Abstract][Full Text] [Related]
9. The higher the growth hormone response to growth hormone releasing hormone the lower the response to bromocriptine and thyrotrophin releasing hormone in acromegaly.
Smals AE; Pieters GF; Smals AG; Hermus AR; Benraad TJ; Kloppenborg PW
Clin Endocrinol (Oxf); 1987 Jul; 27(1):43-7. PubMed ID: 3115634
[TBL] [Abstract][Full Text] [Related]
10. Changes in growth hormone (GH) secretion induced by human pancreatic GH releasing hormone-44 in acromegaly: a comparison with thyrotropin-releasing hormone and bromocriptine.
Chiodini PG; Liuzzi A; Dallabonzana D; Oppizzi G; Verde GG
J Clin Endocrinol Metab; 1985 Jan; 60(1):48-52. PubMed ID: 3917270
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
[TBL] [Abstract][Full Text] [Related]
12. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly.
Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ; Liuzzi A
Acta Endocrinol (Copenh); 1983 Aug; 103(4):446-50. PubMed ID: 6310918
[TBL] [Abstract][Full Text] [Related]
13. Changes in plasma GH levels and clinical activity during bromocriptine therapy in acromegaly. The value of predictive tests.
Nortier JW; Croughs RJ; Donker GH; Thijssen JH; Schwarz F
Acta Endocrinol (Copenh); 1984 Jun; 106(2):175-83. PubMed ID: 6145276
[TBL] [Abstract][Full Text] [Related]
14. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly.
de Herder WW; Taal HR; Uitterlinden P; Feelders RA; Janssen JA; van der Lely AJ
Eur J Endocrinol; 2005 Jul; 153(1):67-71. PubMed ID: 15994747
[TBL] [Abstract][Full Text] [Related]
15. Effect of bromocriptine on serum hormones in acromegaly.
Carlson HE; Levin SR; Braunstein GD; Spencer EM; Wilson SE; Hershman JM
Horm Res; 1984; 19(3):142-52. PubMed ID: 6425186
[TBL] [Abstract][Full Text] [Related]
16. Effects of pirenzepine, bromocriptine and their association on basal and GHRH- and TRH-induced GH secretion in acromegaly.
Fiszlejder L; Penacini O; Ratz S; Storani M; Oneto A; Guitelman A
Horm Res; 1991; 36(1-2):47-51. PubMed ID: 1814801
[TBL] [Abstract][Full Text] [Related]
17. Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly.
Arihara Z; Sakurai K; Yamashita R; Niitsuma S; Ueno T; Yamamura N; Yamada S; Inoshita N; Takahashi K
Tohoku J Exp Med; 2014 Oct; 234(2):129-35. PubMed ID: 25253414
[TBL] [Abstract][Full Text] [Related]
18. Bromocriptine therapy in acromegaly: use in patients resistant to conventional therapy and effect on serum levels of somatomedin C.
Moses AC; Molitch ME; Sawin CT; Jackson IM; Biller BJ; Furlanetto R; Reichlin S
J Clin Endocrinol Metab; 1981 Oct; 53(4):752-8. PubMed ID: 6793607
[TBL] [Abstract][Full Text] [Related]
19. Effect of thyrotropin-releasing hormone and bromoergocriptine on growth hormone and prolactin secretion in perfused pituitary adenoma tissues of acromegaly.
Ishibashi M; Yamaji T
J Clin Endocrinol Metab; 1978 Dec; 47(6):1251-6. PubMed ID: 122426
[TBL] [Abstract][Full Text] [Related]
20. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation.
Oppizzi G; Petroncini MM; Dallabonzana D; Cozzi R; Verde G; Chiodini PG; Liuzzi A
J Clin Endocrinol Metab; 1986 Dec; 63(6):1348-53. PubMed ID: 2878007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
